For decades, Eve Baer remained convinced that her son, unresponsive after a severe brain injury, was still conscious. Science ...

We believe Vertex is in strong financial health, given its robust cash flow generation and low debt. At the end of 2024, Vertex held about $11.2 billion in cash and equivalents.

Today Vertex CF medicines are treating over 68,000 people ... Mall, M.D., in this press release, statements regarding the expected eligible patient population for ALYFTREK, if approved, and ...

Vertex Pharmaceuticals remains on hold with a $494 price target from Stifel analysts after discussions about its chronic pain ...

Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. Vertex's business and prospects remain attractive.

Vertex Pharmaceuticals is diversifying its already strong lineup of medicines. Axsome Therapeutics has multiple clinical and ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

With this approval approximately 45 people[i] living with cystic fibrosis, many with a rare mutation, will be newly eligible for a medicine that ...

Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.

Sources say that a climate of fear has spread throughout the agency as the Trump administration takes a hatchet to its core ...

Barclays has nudged Vertex Pharmaceuticals’ price target to $499, despite a mixed bag in its Q1 performance. Vertex saw a 3% ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...